Global Gammaretroviral Vector Market, By Type (Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Other), Disease Type (Cancer, Genetic Disorders, Infectious Diseases, Other), Application (Gene Therapy, Vaccinology), End-User (Pharmaceutical and Biopharmaceutical, Research Institutes) - Industry Trends and Forecast to 2030.
Gammaretroviral Vector Market Analysis and Size
Retroviruses are naturally adapted gene carriers that have evolved to efficiently deliver their nucleic acids into the target cell chromatin, thereby overcoming natural cellular barriers. Murine Leukemia Virus (MLV), a simple gammaretrovirus, can be converted into an efficient vehicle of genetic therapeutics, beginning with a deeper look into retroviral biology. Retroviral vectors are fascinating and effective nucleic acid delivery vehicles. All retroviruses can reverse-transcribe their single-stranded RNA genome into double-stranded DNA, which is then stably integrated into the host cell genome. As highly evolved parasites, they work with cellular host factors to deliver their nucleic acid into the nucleus, where they use the host cell's machinery for replication and long-term expression.
Data Bridge Market Research analyses that the gammaretroviral vector market which is expected to reach at a CAGR of 17.7% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Gammaretroviral Vector Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Million, Volumes in Units, Pricing in USD
Type (Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Other), Disease Type (Cancer, Genetic Disorders, Infectious Diseases, Other), Application (Gene Therapy, Vaccinology), End-User (Pharmaceutical and Biopharmaceutical, Research Institutes)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Novasep (France), MerckKGaA (Germany), Charles River Laboratories (U.K.), uniQure N.V. (Netherlands), Waisman Biomanufacturing (U.S.), Creative-Biogene (U.S.), Aldevron (U.S.), Addgene (U.S.), Oxford Biomedica (U.K.), Thermo Fisher Scientific Inc (U.S.), Fujifilm Corporation (Japan), Spark Therapeutics Inc. (U.S.), ABL Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Brammer Bio (U.S.), Creative Biogene (U.S.), General Electric (U.S.), Pfizer Inc. (U.S.)
Gammaretroviruses are retroviral vectors in laboratory studies. These vectors are critical for gene therapy and gene transfer. They are so helpful because their genomes are simple and easy to use. Gammaretroviruses have a wide range of implications for animals. They have been linked to various diseases, including cancer, specifically leukemias and lymphomas, neurological diseases, and immunodeficiencies in multiple species. Gammaretroviruses, like other retroviruses, reverse transcribe a positive single strand RNA into double stranded DNA. The double-stranded DNA is highly stable and easily integrated into the host genome. Moloney murine leukaemia virus, xenotropic MuLB-related virus, feline leukaemia virus, and feline sarcoma virus are some examples of the virus.
Global Gammaretroviral Vector Market Dynamics
- Rising prevalence of cancer and genetic disorders
According to the World Health Organization, lung cancer is the leading cause of cancer death, followed by breast cancer and colorectal cancer. Breast cancer, lung cancer, prostate cancer, colon cancer, and rectum cancer are the most frequent cancers. The rising frequency of cancer, genetic illnesses, and infectious diseases is boosting demand for vector-based gene treatments, cell therapies, and vaccines, which is one of the primary drivers of the global gammaretroviral vector market.
- Rapid uptake of viral and plasmid vectors for the development of innovative therapies
Novel medicines are rapidly being developed using viral and non-viral vectors. These vectors are useful for delivering a gene to a specific cell or tissue in vivo. Adeno-associated virus, lentivirus, and retrovirus are examples of viral vectors that have been employed in various clinical and preclinical trials evaluating gene and cell therapy products and vaccines.
Furthermore, the development of stable producer cell lines during upstream processing can provide numerous advantages over relying on transient transfection methods. In addition to saving money on clinical-grade plasmids and transfection agents, viral particles produced by stable cell lines are frequently of higher quality. Because they will be near-homologous, they will reduce potential batch-to-batch variability and provide cleaner harvests. Stable producer cell lines are also more scalable than transient transfection methods, and can be used for small-scale or large-scale production depending on the quantities required.
- Favourable funding scenario for vector-based therapies
High expense of producing and developing a new medicine, preclinical and clinical trials to determine its effectiveness require enough funding. The abundant grants and finances available for undertaking research and development activities connected to vector-based cell and gene therapies propelling the gammaretroviral vector market.
- Rising prevalence of diseases
The rising prevalence of diseases such as heart disease, cancer, HIV, and haemophilia has necessitated the development of viral vector-based therapeutics, with technological advancements in viral vector manufacturing driving market expansion. Furthermore, expanding biopharmaceutical industry usage of viral vectors and increasing cost-effective treatments are driving market demand.
- High cost
High cost of production and gene therapies will limit the growth of gammaretroviral vector market in the forecast period of 2023 to 2030.
This gammaretroviral vector market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the gammaretroviral vector market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Gammaretroviral Vector Market Scope
The gammaretroviral vector market is segmented on the basis of type, disease type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Lentiviral Vectors
- Adenoviral Vectors
- Adeno-Associated Viral Vectors
- Genetic Disorders
- Infectious Diseases
- Gene Therapy
- Pharmaceutical and Biopharmaceutical
- Research Institutes
Gammaretroviral Vector Market Regional Analysis/Insights
The gammaretroviral vector market is analyzed and market size insights and trends are provided by country, type, disease type, application and end-user as referenced above.
The countries covered in the gammaretroviral vector market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the gammaretroviral vector market due to the rising advancement in medical treatment procedures and growing healthcare expenditure.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the rising demand for efficient treatment procedure, increasing funding for gene therapies, and government initiatives for R&D activities in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The gammaretroviral vector market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for gammaretroviral vector market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the gammaretroviral vector market. The data is available for historic period 2011-2021.
Competitive Landscape and Gammaretroviral Vector Market Share Analysis
The gammaretroviral vector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to gammaretroviral vector market.
Some of the major players operating in the gammaretroviral vector market are:
- Novasep (France)
- MerckKGaA (Germany)
- Charles River Laboratories (U.K.)
- uniQure N.V. (Netherlands)
- Waisman Biomanufacturing (U.S.)
- Creative-Biogene (U.S.)
- Aldevron (U.S)
- Addgene (U.S.)
- Oxford Biomedica (U.K.)
- Thermo Fisher Scientific Inc (U.S.)
- Fujifilm Corporation (Japan)
- Spark Therapeutics Inc. (U.S.)
- ABL Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Brammer Bio (U.S.)
- Creative Biogene (U.S.)
- General Electric (U.S.)
- Pfizer Inc. (U.S.)
Research Methodology: Global Gammaretroviral Vector Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.